Study Overview: This study is for adults with focal segmental glomerulosclerosis (FSGS) - a kidney disease where parts of the kidney filters are scarred. It is testing a drug called praliciguat to see if it helps people with FSGS. The study is in Phase 2, which means it's testing both how well the drug works and its safety.
Participants will either get praliciguat or a placebo (a pill that doesn’t have any medicine) for 24 weeks. After that, everyone will get praliciguat for another 24 weeks.
- Time Commitment: The study lasts for 48 weeks in total.
- Eligibility: You need to have had a kidney test showing FSGS within the past 3 years and meet other health criteria.
- Requirements: You should be on certain medications for your kidneys and have a specific kidney function level to join.
This study is being done at multiple locations, so there might be one near you.
Safety Note: You won’t be able to join if you have certain health conditions like sickle cell disease or high blood sugar levels.
How understandable was the trial content above?
Hard to understand
Easy to understand